10 results about "Disorders skin" patented technology

The present invention relates to compositions comprising at least one lipid-lowering drug or a derivative thereof for the treatment of skin diseases or disorders. In various aspects of the invention, the composition further comprises at least one lipid or a derivative thereof.

The present invention relates to the use of Apoptosis Signal-Regulating Kinase-1 (ASK-1) inhibitor compounds for the treatment of organ diseases and disorders, wherein the organ disease or disorder is selected from a liver, heart disease, kidney, pancreas, spleen, or skin disease or disorder.

The invention provides a novel peptide, CMGN-p1, with skin-regenerating properties. Its origin, synthesis, and functional characterization are described. The peptide consists of a chain of 14 amino acids and stimulates cell proliferation, migration, and adhesion. Its ability to be used as a healing agent for acute and chronic wounds is demonstrated, as it promotes the regeneration and healing of skin and mucous membranes. It may be useful for treating various skin conditions and other related body surfaces.

The present invention provides: an Nrf2 activator; and a pharmaceutical composition for preventing or treating diseases related to activation of Nrf2, comprising the Nrf2 activator. Accordingly, it is possible to effectively prevent or treat oxidative stress- or mitochondrial dysfunction-related neurological diseases or oxidative stress-mediated skin diseases.

The invention relates to aromatic hydrocarbon receptor modulator compounds represented by the following formula I, respective optical isomers, deuterated compounds, prodrugs or pharmaceutically acceptable salts thereof, and a preparation method and application of the aromatic hydrocarbon receptor modulator compounds and the optical isomers, the deuterated compounds, the prodrugs or the pharmaceutically acceptable salts thereof. The compound can be used as an aromatic hydrocarbon receptor regulator for regulating the activity of an aromatic hydrocarbon receptor in a body, and has very important significance on treatment of related diseases such as immunity, inflammation, infection, skin diseases, osteoporosis, cancers and neurodegenerative diseases.

The present application relates to the application of platynecine in the preparation of drugs for preventing and / or treating skin lesions or tumors. The present application first discovers and verifies the direct inhibitory effect of platynecine on GNAQ mutant protein by constructing a "phenotype-function-target" three-in-one hierarchical screening system, and confirms its broad application prospect in treating diseases mediated by abnormal activation of GNAQ, GNA11 or GNA14 or mutation of related sites. The present application finds that platynecine can be used as a direct inhibitor of GNAQ mutant protein, which breaks the long-standing situation of lack of small molecule direct inhibitors for this target. Through SPR (physical binding) and IP1 (functional blocking) double experimental evidences, it is proved that platynecine is a direct inhibitor of GNAQ, not a broad-spectrum cytotoxic compound. Since the molecular weight of platynecine is moderate (464.6 Da), it is easy to be chemically modified and mass-produced; it has the potential to develop transdermal preparations for external use, providing a new direction for drug treatment of skin diseases such as PWS, to replace or supplement the existing laser therapy.

The invention discloses an application of sofalcone as a TRPV3 inhibitor in preparation of a medicine for treating skin diseases. Sofalcone has obvious inhibitory activity on TRPV3 ion channel protein and has an obvious anti-pruritus effect on pruritus model mice. The invention provides a certain research basis for developing the targeted TRPV3 inhibitor with a brand-new structure and researching and developing the medicine for treating skin itch.

The present invention relates to a compound of formula (I),whereinX1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1, X2 and X3 are N;Y is N or CH;W is H or F; with the proviso that when W is F, then X1, X2 and X3 are N;R1 and R2 are independently of each other(i) a morpholinyl of formula (II)wherein the arrow denotes the bond in formula (I); andwherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, CN, or C(O)O—C1-C2alkyl; or R3 and R4 form together a bivalent residue—R5R6— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2—O—CH2—, —CH2—NH—CH2—, or any of the structureswherein the arrows denote the bonds in formula (II); or(ii) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R7; wherein R7 is independently at each occurrence C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxyC1-C3alkyl, C3-C6cycloalkyl; or two R7 substituents form together a bivalent residue —R8R9— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2—O—CH2— or —O—CH2CH2—O—;with the proviso that at least one of R1 and R2 is a morpholinyl of formula II;and prodrugs, metabolites, tautomers, solvates and pharmaceutically acceptable salts thereof, for use in a method of treating a skin disorder in a subject, wherein said skin disorder is a genodermatosis, a vascular anomaly or a skin disorder selected from scleroderma, sclerodermatous chronic graft-versus-host disease, lichen sclerosus, lichen planus, lichen ruber planus and scars.

Use of antisense thiomorpholino oligonucleotides to treat, prevent, or ameliorate the progression of inflammatory skin diseases or conditions such as psoriasis. Specifically, thiomorpholino¬ containing ASOs that target pre-mRNAs associated with inflammatory skin diseases or conditions such as psoriasis.

Disclosed herein are therapeutic compositions comprising a bacteriophage and colloidal oat flour, and methods of using the compositions in the treatment of skin diseases and conditions, including eczema.